‘Strategic Alignment’ Behind Asian Vibativ Deal
This article was originally published in PharmAsia News
Executive Summary
SciClone has picked up rights in China and other selected Asian markets to Theravance's antibiotic Vibativ, expanding its regional anti-infective portfolio and providing its new partner with access to a potentially large market opportunity where resistance problems are spreading.